Idiopathic Pulmonary Fibrosis

• Alveolar Epithelial Injury and Dysfunction: Repetitive injury to alveolar type I pneumocytes (possibly from environmental exposures, gastroesophageal reflux, or genetic predisposition) initiates the pathogenic cascade. Type I pneumocytes undergo apoptosis, creating gaps in the epithelial barrier. Critically, type II pneumocytes fail to undergo normal regenerative responses, instead acquiring a profibrotic phenotype through partial epithelial-mesenchymal transition (EMT). These injured epithelial cells release danger-associated molecular patterns (DAMPs) and secrete pro-fibrotic mediators including transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and osteopontin. Loss of epithelial integrity triggers activation of protease-activated receptors (PARs), particularly PAR-2, which further amplifies fibrotic signaling cascades.

• Fibroblast Activation, Proliferation, and Myofibroblast Differentiation: TGF-β signaling through ALK5 kinase (part of the TGF-β receptor complex) drives the critical transformation of resting fibroblasts into contractile myofibroblasts—cells expressing alpha-smooth muscle actin (α-SMA). Myofibroblasts are the primary matrix-producing cells in IPF. This differentiation is mediated by phosphorylation of Smad2/3 proteins, which translocate to the nucleus and activate pro-fibrotic gene transcription. Additionally, Wnt/β-catenin signaling, Hippo pathway dysregulation, and TIMPs/MMP imbalance contribute to fibroblast expansion and resistance to apoptosis. Fibroblasts accumulate in characteristic fibroblast foci—microscopic aggregates representing sites of active matrix deposition at the alveolar-capillary interface.

• Abnormal Wound Healing and Loss of Resolution: In healthy lungs, wound healing progresses through inflammation → epithelial regeneration → matrix remodeling → resolution. IPF represents a pathologic wound-healing response where normal resolution mechanisms fail. The normal downregulation of TGF-β and inflammatory mediators does not occur, creating a "chronic wound" phenotype. Impaired apoptosis of myofibroblasts (mediated by upregulation of anti-apoptotic molecules like Bcl-2 and loss of pro-apoptotic signals) prevents the normal transition from fibroblast proliferation to programmed cell death. Additionally, collagen cross-linking increases, making the matrix refractory to normal remodeling processes. Loss of the epithelial barrier perpetuates recruitment of inflammatory cells (TH2 cytokines and macrophages) that further amplify TGF-β and other pro-fibrotic factors.

• Genetic Predisposition and Telomere Biology: Genome-wide association studies (GWAS) have identified multiple susceptibility loci, with MUC5B promoter polymorphism (rs35705950) being the strongest and most reproducible risk factor. The MUC5B variant increases expression of the mucin, impairing mucociliary clearance and predisposing to infection-triggered epithelial injury. Additionally, mutations in genes encoding surfactant proteins (SFTPA2, SFTPC), desmoplakin (DSP), tight junction proteins (PARN, TERC, TERT), and telomerase components cause familial pulmonary fibrosis and contribute to sporadic IPF. Critically, telomerase dysfunction and critically short telomeres are present in IPF lung tissue and peripheral blood cells, suggesting accelerated cellular senescence and exhaustion of epithelial regenerative capacity. This genetic substrate explains why IPF typically affects older individuals—telomere attrition is age-dependent.

• Aberrant Inflammatory Response: Although IPF is classified as a "non-inflammatory" interstitial pneumonia (in contrast to hypersensitivity pneumonitis or sarcoidosis), early IPF demonstrates low-grade inflammation with recruitment of pro-fibrotic macrophages (M2 phenotype) and TH2-type lymphocytes. These cells secrete IL-4, IL-5, IL-13, and TGF-β, perpetuating fibroblast activation. The inflammatory infiltrate paradoxically correlates poorly with disease activity; absence of significant inflammation does not prevent progression, highlighting that the myofibroblast-mediated fibrotic response has become self-perpetuating.

• Angiogenesis and Vascular Dysfunction: Progressive fibrosis leads to capillary loss and aberrant neoangiogenesis. Hypoxia-inducible factor-1α (HIF-1α) upregulation drives vascular endothelial growth factor (VEGF) production, leading to formation of abnormal, leaky vessels. This contributes to alveolar edema, further epithelial injury, and establishment of a hypoxic microenvironment that perpetuates fibroblast activation through HIF-1α stabilization—creating a vicious cycle.

• Environmental/Occupational Exposures: Chronic inhalation of environmental agents may trigger the initial epithelial injury that initiates IPF in genetically predisposed individuals. Cigarette smoking increases IPF risk 1.5- to 2-fold, likely through oxidative stress and epithelial injury. Metal exposures (particularly in metalworking, welding, and foundry work involving metal fumes) and wood dust are associated with increased risk. Agricultural exposures (grain, hay) and exposure to mold and fungi may contribute. Critically, gastroesophageal reflux disease (GERD) and aspiration are increasingly recognized as contributors to epithelial injury; IPF patients have high prevalence of GERD and microaspiration.

• Genetic Predisposition: As noted above, familial pulmonary fibrosis (FPF) accounts for approximately 10% of IPF cases (genetic anticipation and earlier age of onset in successive generations). MUC5B rs35705950 promoter polymorphism is present in 35-38% of IPF patients versus 10% of controls; carriers have 6-fold increased risk. Mutations in telomerase genes (TERT, TERC), SFTPA2, SFTPC, and desmoplakin (DSP) cause familial disease and are present in a minority of sporadic IPF. These genetic variants impair epithelial regeneration or increase susceptibility to injury.

• Age and Demographic Factors: Advanced age is the strongest risk factor; IPF incidence increases exponentially after age 60 and peaks in the 7th-8th decades. Male gender confers 1.5-2 fold increased risk. Possible explanations include age-related accumulation of telomere shortening, reduced regenerative capacity, and increased environmental exposures in males.

• Chronic Infections: Although not definitively causative, viral infections (particularly respiratory syncytial virus, influenza, and coronavirus including SARS-CoV-2) may trigger acute exacerbations of IPF. Some evidence suggests chronic hepatitis C infection and EBV may contribute to IPF development, though this remains controversial.

• Autoimmunity and Autoantibodies: IPF patients have increased prevalence of autoantibodies (antinuclear antibodies, rheumatoid factor, anti-centromere) compared to controls, though clinical autoimmune disease is absent by definition. This suggests shared pathogenic mechanisms with connective tissue diseases, though autoimmunity is not primary in IPF.

• Obesity and Metabolic Factors: Obesity correlates with worse IPF prognosis, possibly through metabolic dysfunction and altered adipokine signaling that favors fibrosis.

• Dyspnea on Exertion (DOE): The cardinal symptom, usually the first manifestation. Patients report progressive exertional dyspnea that worsens over time. Initially, dyspnea occurs with strenuous activity (climbing stairs, running); later, it occurs with minimal activity or at rest. The pathophysiological basis involves ventilation-perfusion (V/Q) mismatch from patchy fibrosis, increased alveolar-capillary diffusion distance due to fibrotic thickening, and right ventricular dysfunction from pulmonary hypertension. Some patients initially attribute dyspnea to deconditioning or aging.

• Dry Cough: A non-productive, often irritating cough present in 50-70% of patients at presentation. Cough results from epithelial irritation from ongoing microinjury, loss of normal epithelial clearance mechanisms, and sensitization of cough receptors. Productive cough suggests superimposed infection or alternative diagnosis.

• Chest Discomfort: Pleuritic or non-pleuritic chest pain occurs in a minority, typically resulting from pleural involvement or intercostal muscle strain from labored breathing.

• Constitutional Symptoms: Weight loss (present in 10-15% of patients) and fatigue accompany progressive disease. These result from increased metabolic demands of labored breathing and activation of catabolic pathways.

• Physical Examination Findings:
• Bibasilar Inspiratory "Velcro" Crackles: The pathognomonic finding, heard at lung bases during inspiration. These fine, end-inspiratory crackles result from sudden reopening of collapsed alveoli during inspiration and represent the acoustic signature of fibrosis. Present in ~80% of IPF patients and correlate with fibrotic burden. The term "Velcro crackles" derives from the characteristic sound's resemblance to separating velcro.
• Reduced Breath Sounds: Basilar or diffuse reduction in breath sounds from areas of extensive fibrosis with impaired ventilation.
• Clubbing: Digital clubbing occurs in 25-50% of IPF patients and indicates moderate-to-advanced disease. It develops gradually and may be the only physical sign early in disease. Clubbing in IPF is thought to result from hypoxia-driven angiogenesis and epithelial growth factor signaling.
• Cyanosis: Peripheral cyanosis may develop in advanced disease with severe hypoxemia.
• Right Heart Strain Signs: In advanced disease, cor pulmonale develops with elevated jugular venous pressure, hepatomegaly, peripheral edema, and accentuated P2 (pulmonary hypertension).

• Important Clinical Variants and Presentations:
• Acute Exacerbation of IPF (AE-IPF): A subset of patients (10-15% per year) experience acute, sometimes fulminant worsening of dyspnea, hypoxemia, and radiographic opacities over days to weeks. AE-IPF often triggers irreversible decline and death. Triggers include infections (bacterial or viral), microaspiration, and sometimes no identifiable cause. Pathophysiology involves acute epithelial injury, DAMPs release, and fulminant alveolar edema superimposed on chronic fibrosis.
• Occult Pulmonary Hypertension: Some IPF patients develop disproportionate pulmonary hypertension (PH) relative to the degree of fibrotic burden—termed "disproportionate PH." This results from chronic hypoxia, capillary obliteration by fibrosis, and active vasculopathy. PH significantly worsens prognosis and contributes to exercise limitation.
• Subclinical Disease: A minority of patients are asymptomatic at diagnosis, with disease detected incidentally on imaging performed for other reasons or through screening of at-risk relatives.

• Clinical History and Examination: A detailed history emphasizing symptom onset (insidious vs. acute), duration, progression rate, occupational/environmental exposures, smoking history, and medications is essential. GERD history and symptoms of microaspiration should be elicited. Family history of pulmonary fibrosis in first-degree relatives is important (suggesting genetic predisposition). Physical examination documenting the presence, distribution, and character of crackles, clubbing, and signs of right heart strain is critical. The diagnosis should be suspected in any patient over 50 presenting with insidious dyspnea and bibasilar crackles.

• Pulmonary Function Tests (PFTs):
• Forced Vital Capacity (FVC): Typically reduced (FVC <80% predicted), reflecting restrictive physiology. FVC decline ≥10% represents clinically significant progression.
• Diffusion Capacity for Carbon Monoxide (DLCO): Markedly reduced (DLCO <40% predicted in severe disease), often disproportionate to the FVC reduction. This reflects alveolar-capillary thickening and capillary bed obliteration from fibrosis. Low DLCO at baseline predicts worse prognosis.
• Forced Expiratory Volume in 1 Second (FEV1)/FVC Ratio: Normal to elevated (>0.8), reflecting restriction without obstruction. An FEV1/FVC ratio <0.8 suggests concurrent emphysema or alternative diagnosis.
• Total Lung Capacity (TLC): Reduced (<80% predicted), confirming restrictive pattern.
• Interpretation: The restrictive pattern (reduced FVC, TLC, normal FEV1/FVC, reduced DLCO) is typical for IPF but non-specific. Serial PFT decline with FVC decline >5% per 6 months indicates rapid progression.

• Arterial Blood Gas (ABG) or Pulse Oximetry:
• Hypoxemia: At-rest or exercise-induced hypoxemia (SpO2 <88% on room air at rest or <88% with minimal exertion) is common and prognostically significant.
• Hypercarbia: Elevated PCO2 suggests end-stage disease with significant hypoventilation or acute exacerbation with impending respiratory failure.
• 6-Minute Walk Test (6MWT): Measures exercise capacity and desaturation. A drop >4% in SpO2 or an absolute SpO2 <88% during 6MWT predicts mortality and indicates need for supplemental oxygen during exercise.

• High-Resolution Computed Tomography (HRCT) of the Chest: HRCT is the gold standard imaging study and essential for diagnosis. HRCT patterns are classified according to the Fleischner Society criteria:
• Typical UIP Pattern: The diagnostic HRCT pattern for IPF (equivalent to pathological UIP pattern). Characterized by:
• Reticular opacities (lacy, net-like pattern) predominantly in the peripheral and basilar lung zones
• Traction bronchiectasis (irregular bronchial dilation due to surrounding fibrosis)
• Honeycombing (clustered cystic air spaces of similar size, 3-10 mm diameter, representing end-stage fibrosis with loss of normal lung architecture)
• Absence of features inconsistent with UIP: No upper lobe or apical predominance, no prominent ground-glass opacities,

First-line chronic therapy — antifibrotics (conditionally recommended by ATS/ERS/JRS/ALAT)

• Tyrosine kinase inhibitor: nintedanib blocks VEGFR, FGFR, and PDGFR signaling on fibroblasts, slowing the rate of FVC decline (INPULSIS trials). It does not reverse established fibrosis or clearly restore lost function.
• Pyridone antifibrotic: pirfenidone downregulates TGF-β–driven fibroblast proliferation and collagen synthesis, likewise slowing FVC decline (ASCEND). Neither agent is proven superior; choice is driven by side-effect tolerance.

Supportive care — decided in parallel, not after

• Long-term oxygen: recommended by the ATS for ILD patients with severe resting hypoxemia; ambulatory oxygen for exertional desaturation.
• Pulmonary rehabilitation: improves walk distance and dyspnea.
• Vaccination and smoking cessation: influenza, pneumococcal, and COVID-19 per CDC/ACIP.
• Cough and palliation: low-dose opioids for refractory cough/dyspnea; early palliative care involvement.

Escalation and definitive management

• Lung transplantation is the only intervention that prolongs survival. ISHLT consensus supports referral at the time of diagnosis, not when the patient is failing — waitlist mortality in IPF is high.
• Inhaled treprostinil may be considered for documented pulmonary hypertension associated with ILD (INCREASE), not for IPF alone.

Contraindicated / recommended against

• Triple therapy with prednisone + azathioprine + N-acetylcysteine: increased death and hospitalization in PANTHER-IPF — strongly recommended against.
• Warfarin, ambrisentan, imatinib: recommended against by ATS/ERS/JRS/ALAT.
• Antacid therapy or anti-reflux surgery given specifically to treat IPF: suggested against in the 2022 guideline (treat symptomatic GERD on its own merits).

Disease-related

• Acute exacerbation of IPF (AE-IPF): emergency. Diffuse alveolar damage superimposed on UIP produces acute epithelial injury and alveolar flooding. Signaled by dyspnea worsening over <1 month with new bilateral ground-glass opacities superimposed on the reticular/honeycomb background on HRCT, not explained by heart failure or fluid overload. High in-hospital mortality.
• Progressive respiratory failure: emergency when acute. Loss of alveolar-capillary surface and V/Q mismatch produce refractory hypoxemia; rising PaCO₂ signals terminal decompensation.
• Pulmonary hypertension and cor pulmonale: capillary obliteration plus hypoxic vasoconstriction raise PVR. Signaled by loud P2, elevated JVP, edema, and a DLCO that falls out of proportion to FVC; confirmed by echocardiography/right heart catheterization. Independently worsens survival.
• Lung cancer: fibrotic scarring and epithelial senescence raise risk substantially. Signaled by a new nodule or mass at the periphery of fibrotic lower lobes — easily hidden within honeycombing.
• Combined pulmonary fibrosis and emphysema (CPFE): coexisting upper-lobe emphysema falsely normalizes lung volumes, so FVC looks preserved while DLCO is markedly reduced. Misses the diagnosis if FVC alone is trended.
• Pneumothorax: rupture of subpleural honeycomb cysts; sudden pleuritic pain and desaturation — emergency.
• Venous thromboembolism and infection: both are common precipitants of apparent exacerbation and must be excluded before attributing decline to AE-IPF.

Treatment-related

• Nintedanib: diarrhea (most common, from tyrosine kinase inhibition in gut epithelium), transaminase elevation requiring LFT monitoring, bleeding and arterial thromboembolic events from VEGFR blockade, and teratogenicity.
• Pirfenidone: nausea/anorexia with weight loss, transaminitis, and photosensitivity rash — counsel on sun protection.
• Corticosteroid/immunosuppressive exposure: hyperglycemia, infection, and — as shown with combination immunosuppression — excess mortality.
• Transplantation: primary graft dysfunction, infection under immunosuppression, and chronic rejection as bronchiolitis obliterans syndrome.

• The stem phrase to recognize: an older man, ≥60, with insidious exertional dyspnea, a dry cough, digital clubbing, and fine end-inspiratory Velcro crackles at the bases. That triad is IPF until proven otherwise.
• Single best next step after history/exam: HRCT chest, not surgical lung biopsy. If HRCT shows a typical UIP pattern — subpleural, basal-predominant reticulation with traction bronchiectasis and honeycombing — in the right clinical context, the ATS/ERS/JRS/ALAT guideline permits diagnosis without biopsy.
• The PFT signature: reduced FVC and TLC with a normal or elevated FEV1/FVC ratio and a disproportionately low DLCO. Restriction with a preserved ratio is the discriminator from COPD.
• The association examiners love: the MUC5B promoter polymorphism (rs35705950) — the strongest genetic risk factor — and telomerase mutations (TERT/TERC) in familial pulmonary fibrosis, which may present with early graying and bone marrow failure.
• The therapeutic point: only nintedanib (triple tyrosine kinase inhibitor) and pirfenidone slow FVC decline; neither reverses fibrosis or clearly reduces mortality. Only lung transplantation prolongs survival, and ISHLT advises referral at diagnosis.
• The classic distractor: reaching for corticosteroids or immunosuppression. Prednisone + azathioprine + N-acetylcysteine increased mortality in PANTHER-IPF and is contraindicated. IPF is not a steroid-responsive ILD — that framing belongs to hypersensitivity pneumonitis, sarcoidosis, and NSIP.
• Distinguish look-alikes: asbestosis gives basilar fibrosis plus pleural plaques and an exposure history; hypersensitivity pneumonitis is upper/mid-lobe with mosaic attenuation and air trapping; NSIP shows homogeneous ground-glass with subpleural sparing and suggests connective tissue disease — always send ANA, RF, and anti-CCP.
• Acute worsening over days to weeks with new ground-glass on a fibrotic background = acute exacerbation; first exclude PE, infection, and heart failure before labeling it AE-IPF.